Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

被引：0

作者：

Kawachi, H. ^{[1
]}

Tamiya, M. ^{[1
]}

Tamiya, A. ^{[2
]}

Ishii, S. ^{[2
]}

Hirano, K. ^{[3
]}

Matsumoto, H. ^{[3
]}

Yokoyama, T. ^{[4
]}

Ishida, T. ^{[4
]}

Ryota, K. ^{[5
]}

Fujimoto, D. ^{[6
]}

Hosoya, K. ^{[6
]}

Suzuki, H. ^{[7
]}

Hirashima, T. ^{[8
]}

Kanazu, M. ^{[9
]}

Sawa, N. ^{[10
]}

Uchida, J. ^{[11
]}

Morita, M. ^{[12
]}

Makio, T. ^{[13
]}

Hara, S. ^{[13
]}

Kumagai, T. ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan

[2] Kinki Chuo Chest Med Ctr, Internal Med, Sakai, Osaka, Japan

[3] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan

[4] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[5] Himeji Med Ctr, Resp Med, Himeji, Hyogo, Japan

[6] Kobe City Med Ctr Gen Hosp, Resp Med, Kobe, Hyogo, Japan

[7] Osaka Habikino Med Ctr, Thorac Oncol, Habikino, Japan

[8] Osaka Prefectural Habikino Hosp, Thorac Oncol, Habikino, Japan

[9] Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[10] Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[11] Osaka Gen Med Ctr, Resp Med, Osaka, Japan

[12] Kobe City Med Ctr West Hosp, Resp Med, Kobe, Hyogo, Japan

[13] Itami City Hosp, Resp Med, Itami, Hyogo, Japan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1514P

引用

页数：1

共 50 条

[31] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre
Laurent Greillier
Grégoire Justeau
Charles Ricordel
Aurélie Swalduz
Hubert Curcio
Olivier Bylicki
Jean-Bernard Auliac
Florian Guisier
Laurence Bigay-Game
Marie Bernardi
Julian Pinsolle
Karim Amrane
Chantal Decroisette
Renaud Descourt
Christos Chouaid
Margaux Geier
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15095 - 15102
[32] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Doubre, Helene
Greillier, Laurent
Justeau, Gregoire
Ricordel, Charles
Swalduz, Aurelie
Curcio, Hubert
Bylicki, Olivier
Auliac, Jean-Bernard
Guisier, Florian
Bigay-Game, Laurence
Bernardi, Marie
Pinsolle, Julian
Amrane, Karim
Decroisette, Chantal
Descourt, Renaud
Chouaid, Christos
Geier, Margaux
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15095 - 15102
[33] Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
Kaira, Kyoichi
Yamaguchi, Ou
Kawasaki, Tomonori
Hashimoto, Kousuke
Miura, Yu
Shiono, Ayako
Mouri, Atsuto
Imai, Hisao
Kobayashi, Kunihiko
Yasuda, Masanori
Kagamu, Hiroshi
DISCOVER ONCOLOGY, 2023, 14 (01)
[34] Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
Kyoichi Kaira
Ou Yamaguchi
Tomonori Kawasaki
Kousuke Hashimoto
Yu Miura
Ayako Shiono
Atsuto Mouri
Hisao Imai
Kunihiko Kobayashi
Masanori Yasuda
Hiroshi Kagamu
Discover Oncology, 14
[35] Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
Jin, Chen-xing
Liu, Yan-song
Qin, He-nan
Teng, Yi-bin
Sun, Rui
Ma, Zhong-jing
Wang, A-man
Liu, Ji-wei
SCIENTIFIC REPORTS, 2025, 15 (01):
[36] A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
Wu, Kai
Fu, Yifan
Zeng, Daxiong
Chen, Tao
Wang, Changguo
Jiang, Junhong
JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 679 - 688
[37] The Scottish Immunotherapy Prognostic Score (SIPS) Predicts Response to First-Line Pembrolizumab for Metastatic Non-Small Cell Lung Cancer
Stares, M.
Ding, T.
Stratton, C.
Thomson, F.
Mackean, M.
Cumming, K.
Barrie, C.
Maclennan, K.
Campbell, S.
Evans, T.
Tufail, A.
Phillips, I.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1139 - S1140
[38] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%
Descourt, Renaud
Chouaid, Christos
Perol, Maurice
Besse, Benjamin
Greillier, Laurent
Bylicki, Olivier
Ricordel, Charles
Guisier, Florian
Gervais, Radj
Schott, Roland
Auliac, Jean-Bernard
Robinet, Gilles
Decroisette, Chantal
FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016
[39] Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.
Aguilar, Elizabeth Jimenez
Rizvi, Hira
Kravets, Sasha
Lydon, Christine A.
Adeni, Anika E.
Subegdjo, Safiya
Hellmann, Matthew David
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
Metro, Giulio
Banna, Giuseppe Luigi
Signorelli, Diego
Gili, Alessio
Galetta, Domenico
Galli, Giulia
Economopoulou, Panagiota
Roila, Fausto
Friedlaender, Alex
Camerini, Andrea
Christopoulou, Athina
Cantale, Ornella
De Toma, Alessandro
Pizzutilo, Pamela
Jimenez, Beatriz
Collazo-Lorduy, Ana
Calles, Antonio
Baxevanos, Panagiotis
Linardou, Helena
Kosmidis, Paris
Giannarelli, Diana
Mountzios, Giannis
Addeo, Alfredo
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306

← 1 2 3 4 5 →